Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption

E. A. Neuwelt, J. T. Diehl, L. H. Vu, S. A. Hill, A. J. Michael, E. P. Frenkel

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Reversible transient osmotic blood-brain barrier disruption was used to increase drug delivery to the brain. Methotrexate was administered 33 times to 6 patients with brain tumors after barrier disruption. No permanent complications were seen. Serial enhanced computed tomographic (CT) scans and quantification by CT tomographic number indicated that disruption increased drug delivery to the tumor and immediate surrounding brain. Neuroradiologic evaluation showed that drug in the tumor persisted longer after barrier disruption than when delivered without disruption. The concentration of methotrexate in spinal fluid did not correlate with the degree of barrier disruption measured by CT and radionuclide scans. In 1 patient an anatomic variation in the circle of Willis resulted in barrier disruption extending into the posterior fossa without ill effect. Osmotic blood-brain barrier disruption appears to be a safe procedure in man, able to increase drug delivery to both malignant brain tumors and surrounding brain parenchyma.

Original languageEnglish (US)
Pages (from-to)449-454
Number of pages6
JournalAnnals of Internal Medicine
Volume94
Issue number4 I
StatePublished - 1981

Fingerprint

Blood-Brain Barrier
Methotrexate
Brain Neoplasms
Brain
Pharmaceutical Preparations
Circle of Willis
Anatomic Variation
Drug Evaluation
Radioisotopes
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. / Neuwelt, E. A.; Diehl, J. T.; Vu, L. H.; Hill, S. A.; Michael, A. J.; Frenkel, E. P.

In: Annals of Internal Medicine, Vol. 94, No. 4 I, 1981, p. 449-454.

Research output: Contribution to journalArticle

Neuwelt, E. A. ; Diehl, J. T. ; Vu, L. H. ; Hill, S. A. ; Michael, A. J. ; Frenkel, E. P. / Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. In: Annals of Internal Medicine. 1981 ; Vol. 94, No. 4 I. pp. 449-454.
@article{6bbce7b386c64980830e7193a3f966f4,
title = "Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption",
abstract = "Reversible transient osmotic blood-brain barrier disruption was used to increase drug delivery to the brain. Methotrexate was administered 33 times to 6 patients with brain tumors after barrier disruption. No permanent complications were seen. Serial enhanced computed tomographic (CT) scans and quantification by CT tomographic number indicated that disruption increased drug delivery to the tumor and immediate surrounding brain. Neuroradiologic evaluation showed that drug in the tumor persisted longer after barrier disruption than when delivered without disruption. The concentration of methotrexate in spinal fluid did not correlate with the degree of barrier disruption measured by CT and radionuclide scans. In 1 patient an anatomic variation in the circle of Willis resulted in barrier disruption extending into the posterior fossa without ill effect. Osmotic blood-brain barrier disruption appears to be a safe procedure in man, able to increase drug delivery to both malignant brain tumors and surrounding brain parenchyma.",
author = "Neuwelt, {E. A.} and Diehl, {J. T.} and Vu, {L. H.} and Hill, {S. A.} and Michael, {A. J.} and Frenkel, {E. P.}",
year = "1981",
language = "English (US)",
volume = "94",
pages = "449--454",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4 I",

}

TY - JOUR

T1 - Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption

AU - Neuwelt, E. A.

AU - Diehl, J. T.

AU - Vu, L. H.

AU - Hill, S. A.

AU - Michael, A. J.

AU - Frenkel, E. P.

PY - 1981

Y1 - 1981

N2 - Reversible transient osmotic blood-brain barrier disruption was used to increase drug delivery to the brain. Methotrexate was administered 33 times to 6 patients with brain tumors after barrier disruption. No permanent complications were seen. Serial enhanced computed tomographic (CT) scans and quantification by CT tomographic number indicated that disruption increased drug delivery to the tumor and immediate surrounding brain. Neuroradiologic evaluation showed that drug in the tumor persisted longer after barrier disruption than when delivered without disruption. The concentration of methotrexate in spinal fluid did not correlate with the degree of barrier disruption measured by CT and radionuclide scans. In 1 patient an anatomic variation in the circle of Willis resulted in barrier disruption extending into the posterior fossa without ill effect. Osmotic blood-brain barrier disruption appears to be a safe procedure in man, able to increase drug delivery to both malignant brain tumors and surrounding brain parenchyma.

AB - Reversible transient osmotic blood-brain barrier disruption was used to increase drug delivery to the brain. Methotrexate was administered 33 times to 6 patients with brain tumors after barrier disruption. No permanent complications were seen. Serial enhanced computed tomographic (CT) scans and quantification by CT tomographic number indicated that disruption increased drug delivery to the tumor and immediate surrounding brain. Neuroradiologic evaluation showed that drug in the tumor persisted longer after barrier disruption than when delivered without disruption. The concentration of methotrexate in spinal fluid did not correlate with the degree of barrier disruption measured by CT and radionuclide scans. In 1 patient an anatomic variation in the circle of Willis resulted in barrier disruption extending into the posterior fossa without ill effect. Osmotic blood-brain barrier disruption appears to be a safe procedure in man, able to increase drug delivery to both malignant brain tumors and surrounding brain parenchyma.

UR - http://www.scopus.com/inward/record.url?scp=0019508765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019508765&partnerID=8YFLogxK

M3 - Article

VL - 94

SP - 449

EP - 454

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4 I

ER -